The intricate biochemical pathways within the human brain are fundamental to our cognitive functions, emotional well-being, and overall neurological health. Central to many of these vital processes is tryptophan, an essential amino acid, more commonly associated with its role in promoting sleep. However, its influence extends far beyond inducing drowsiness; tryptophan serves as a critical precursor for a cascade of essential molecules. It is instrumental in the synthesis of proteins, the generation of cellular energy currency in the form of NAD+, and the production of key neurotransmitters like serotonin and melatonin. These neurochemical building blocks collectively underpin mood regulation, facilitate learning processes, and ensure the maintenance of robust sleep-wake cycles.
As the brain navigates the challenges of aging or confronts the complexities of neurodegenerative and psychiatric disorders, this finely tuned biochemical machinery can begin to falter. Scientific investigations have consistently documented alterations in the way the brain metabolizes tryptophan in older individuals, with more pronounced disruptions observed in the context of conditions such as Alzheimer’s disease, Parkinson’s disease, and various mental health conditions. These observed dysregulations are frequently correlated with an exacerbation of mood disturbances, a decline in learning capacity, and significant disruptions to sleep patterns, creating a detrimental cycle of neurological impairment. Despite accumulating evidence of these tryptophan processing anomalies, the underlying molecular trigger that initiates this shift in metabolic direction remained elusive until recent groundbreaking research.
A significant breakthrough has illuminated the intricate mechanisms governing tryptophan’s fate within the brain, identifying a pivotal regulatory protein. Researchers at Ben-Gurion University of the Negev, led by Professor Debra Toiber, have pinpointed a longevity-associated protein, Sirtuin 6 (SIRT6), as the principal architect behind these critical metabolic imbalances. Their comprehensive study, employing a multi-faceted experimental approach across cellular models, fruit fly (Drosophila) systems, and mammalian mouse models, provides compelling evidence for SIRT6’s active role in orchestrating gene expression. Specifically, SIRT6 exerts control over genes involved in tryptophan metabolism, such as TDO2 (tryptophan 2,3-dioxygenase) and AANAT (arylalkylamine N-acetyltransferase), enzymes that dictate which biochemical pathway tryptophan will enter.
The research meticulously demonstrates that a decline in SIRT6 levels results in a loss of this essential regulatory control. When SIRT6 activity diminishes, the brain’s metabolic machinery undergoes a critical redirection. Instead of favoring pathways that generate beneficial neurochemicals, tryptophan is increasingly shunted towards the kynurenic acid pathway. This alternative route is known to produce compounds that can exert neurotoxic effects, potentially contributing to neuronal damage and dysfunction. Concurrently, the production of neuroprotective neurotransmitters, including serotonin and melatonin, which are vital for mood stability and healthy sleep, experiences a significant reduction. This metabolic switch, driven by SIRT6 deficiency, thus represents a fundamental shift from neuroprotection to neurotoxicity, impacting brain health on multiple levels.
The implications of these findings are profound, offering a new perspective on the molecular underpinnings of age-related cognitive decline and neurological diseases. The study, recently published in the esteemed scientific journal Nature Communications, provides a detailed account of the experimental evidence supporting this critical role of SIRT6. The research team’s rigorous investigations have not only identified the problem but have also uncovered a glimmer of hope regarding the reversibility of the damage.
Crucially, the scientists discovered that the detrimental consequences of this metabolic shift are not necessarily permanent. In experiments involving a SIRT6 knockout fly model, where the protein’s function was experimentally abolished, researchers were able to observe the impact of intervening in the downstream metabolic consequences. By pharmacologically blocking the enzyme TDO2, a key player in the kynurenic acid pathway, the team observed a remarkable improvement in motor deficits that are often indicative of neurological impairment in these models. Furthermore, this intervention led to a reduction in the formation of vacuoles, cellular structures that serve as markers of brain tissue damage. These compelling results strongly suggest that there exists a therapeutic window, a critical period during which interventions aimed at restoring or rerouting tryptophan metabolism could potentially mitigate or even reverse neurological damage.
Professor Toiber articulated the significance of their findings, stating, "Our research positions SIRT6 as a critical, upstream drug target for combating neurodegenerative pathology." This statement underscores the potential of targeting SIRT6 or its downstream effectors as a novel therapeutic strategy for a range of neurological conditions. By addressing the root cause of the metabolic imbalance, rather than solely managing symptoms, future treatments could offer more effective and potentially disease-modifying interventions.
The collaborative effort behind this groundbreaking research involved a distinguished team of scientists, including Shai Kaluski-Kopatch, Daniel Stein, Alfredo Garcia Venzor, Ana Margarida Ferreira Campos, Melanie Planque, Bareket Goldstein, EstefanÃa De Allende-Becerra, Dmitrii Smirnov, Adam Zaretsky, Dr. Ekaterina Eremenko-Sgibnev, Miguel Portillo, Monica Einav, Alena Bruce Krejci, Uri Abdu, Ekaterina Khrameeva, Daniel Gitler, and Sarah-Maria Fendt. Their collective expertise and dedication were instrumental in unraveling the complex molecular mechanisms at play.
This extensive research initiative was generously supported by a consortium of prestigious funding bodies, reflecting the global recognition of its importance. The European Research Council (ERC) provided substantial support under the European Union’s Horizon 2020 research and innovation program (grant agreement No 849029), underscoring the project’s alignment with Europe’s strategic research priorities. Additional funding was provided by the David and Inez Myers Foundation, the Israeli Ministry of Science and Technology (MOST), and fellowships from the Kreitman School of Advanced Research at Ben-Gurion University, including the High-tech, Bio-tech, and Negev fellowships. The Israel Science Foundation also contributed vital support through grant no. 422/23. The crucial RNA-seq data analysis, which provided essential insights into gene expression patterns, was further supported by the Russian Science Foundation under grant number 25-71-20017. This multi-faceted financial backing highlights the international collaborative nature and significant scientific merit of this endeavor, paving the way for future explorations into brain health and disease.
About the Author
